Copy
September 10, 2019
Giving healthcare companies the exposure they deserve. Every Tuesday.
BioTuesdays by Kilmer Lucas
Share
Tweet
Share
Forward

FEATURED STORY

DelMar Pharma developing VAL-083 in biomarker-driven GBM patient populations

DelMar Pharmaceuticals (NASDAQ:DMPI) is conducting two Phase 2 clinical trials with its lead drug candidate, VAL-083, a DNA-targeting agent, in three distinct biomarker-driven glioblastoma multiforme (GMB) patient populations.

“Previous work at the NCI and additional data from our own studies have demonstrated that VAL-083 crosses the blood-brain barrier, has biological and tumor effecting activity against a range of cancers, including GBM and ovarian and resulted in a safety database of more than 1,000 patients,” Saiid Zarrabian, president and CEO of DelMar, says in an interview with BioTuesdays.

“Effectively, we are in two highly de-risked late-stage Phase 2 programs, targeting MGMT-unmethylated GBM tumors, which more than 60% of GBM patients have,” he adds. Methylguanine DNA-methyltransferase (MGMT) is a DNA repair enzyme.
Read the Story

SELECT BRIEFS

NASDAQ:PRPO

Precipio

Precipio and U of Penn in joint pathology diagnostics collaboration
 

 

Soricimed Biopharma

Image Analysis Group to validate SOR-C13 imaging markers
 

 

Spartan Bioscience

Boosts executive team
 

 

Versant Ventures

Launches medtech sector investment firm
 

More Briefs


Markets


About BioTuesdays

 
BioTuesdays was created in 2009 by Kilmer Lucas, a leading healthcare-only investor relations firm. Employing a unique "outsourced in-house" partnership model, Kilmer Lucas designs and executes customized IR & PR programs for its drug development, medical device, cell therapy, diagnostics and healthcare services clients. But, most of BioTuesdays' content isn't client-driven. Rather, our mission is to give as many great healthcare companies and their stories as much exposure as we can.
Want to be featured in BioTuesdays? Get in touch with us.
Copyright © 2019 Kilmer Lucas, All rights reserved.
You are receiving this email because you signed up for the BioTuesdays newsletter.
Privacy Policy

BioTuesdays
PO Box 297
Carlisle, ON L0R 1H0 

subscribe | unsubscribe | update your preferences